difference between dose limits and constraints

Dose limits and dose constraints are both tools used in radiation protection, but they serve different purposes and apply in different contexts.

Dose limits are legally binding maximum values of radiation dose that must not be exceeded for workers or members of the public. They are set by regulatory authorities (based on ICRP recommendations) and apply to planned exposure situations. Exceeding them is a regulatory violation.

Dose constraints are prospective, source-related values used during the design and optimization stage of a practice. They are lower than dose limits and act as an upper bound during the optimization (ALARA) process for a specific source. They are not legal limits - exceeding a constraint triggers a review, not a legal breach.

Searching sources...

Searching the Web

dose limits vs dose constraints radiation protection ICRP difference

Reading File

This topic is radiation protection (physics/health physics), not a clinical medical question, so I'll synthesize from the web search results and my knowledge.

Dose Limits vs. Dose Constraints

Here is a structured comparison based on ICRP Publication 103 (the primary international framework):

Dose Limits

Feature	Detail
Nature	Legally binding regulatory values
Purpose	Set a hard ceiling - doses above this are NOT permitted
Set by	National regulatory bodies (based on ICRP recommendations)
Applies to	Occupational and public exposures in planned situations only
Does NOT apply to	Medical exposures of patients (diagnosis/treatment)
Consequence of exceeding	Regulatory violation - unlawful
Scope	Cumulative dose from ALL sources combined

Current ICRP 103 dose limits:

Workers: 20 mSv/year averaged over 5 years (max 50 mSv in any single year), effective dose
Public: 1 mSv/year effective dose
Lens of the eye (workers): 20 mSv/year (updated ICRP 118)
Skin/extremities (workers): 500 mSv/year equivalent dose

Dose Constraints

Feature	Detail
Nature	Prospective, non-binding planning tool
Purpose	Upper bound used during optimization (ALARA/ALARP) for a single specific source
Set by	Operator, employer, or regulatory body - source-specific
Applies to	Planned, emergency, and existing exposure situations
Significance in medical exposure	Particularly important here since dose limits don't apply to patients
Consequence of exceeding	Triggers a review/follow-up action - NOT a legal violation
Scope	Single source only (not cumulative from all sources)

For planned exposures that already have a dose limit, the constraint must always be set below that limit.

Key Conceptual Differences

Dimension	Dose Limit	Dose Constraint
Binding?	Yes - regulatory/legal	No - operational/planning tool
When applied?	Retrospectively checked for compliance	Prospectively used in design/optimization
Source scope	All sources combined	Per-source (one source at a time)
Role in ICRP framework	3rd principle: Dose Limitation	2nd principle: Optimization of Protection
Exceeding triggers...	Non-compliance/legal breach	Review and corrective action
Applies in emergencies?	No (reference levels used instead)	Yes (adapted form)
Applies to patients?	No	Yes (in absence of dose limits)

Practical Example

A nuclear power plant worker has:

A dose constraint of 10 mSv/year set by the operator for a specific maintenance task (source-specific, optimization tool)
A dose limit of 20 mSv/year (averaged) set by the regulator

The worker can receive dose from multiple tasks/sources. If their total from this one task exceeds 10 mSv, a review is triggered. If their cumulative dose from ALL work exceeds 20 mSv, they are in regulatory violation.

Why the Distinction Matters

The ICRP introduced constraints specifically to strengthen the optimization principle - you shouldn't just stay below the limit, you should actively minimize doses. Constraints push protection further down from the legal ceiling. As ICRPaedia notes, "dose limits alone are not enough to ensure adequate protection" - they work alongside justification and optimization. The European Commission clarifies that constraints "are not a limit and do not represent a demarcation between safe and dangerous levels" - they are purely an optimization tool.

i dont know how to report fdg brain pet ct in case of autoimmune encephalitis. give me a detailed list of what i need to look for and wat are the different types of AIE and how to interpret each

Reading File

This is a detailed clinical/imaging question. Let me run parallel searches across the medical library and web simultaneously.

Finding Sources

Searching the Web

FDG PET brain reporting autoimmune encephalitis anti-NMDA LGI1 GABA patterns hypometabolism hypermetabolism

Excellent data collected. Now let me read the textbook section and extract images in parallel.

Reading File

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC9996532

Searching Images

FDG PET brain autoimmune encephalitis hypermetabolism hypometabolism pattern

This diagnostic image displays 18F-FDG PET (fluorodeoxyglucose positron emission tomography) brain scans from a 60-year-old male presenting with seizures and memory impairment. The figure includes two rows of multi-planar reconstructions: the top row shows absolute metabolic uptake maps (SSP PET), and the bottom row displays corresponding semi-quantitative Z-score maps (SSP Z-Score) comparing the patient to a normative database. Visualized planes include lateral and medial surface views, as well as anterior, posterior, superior, and inferior projections. The Z-score maps utilize a colorimetric scale where cool colors (blue/green) represent hypometabolism and warm colors (red/orange) represent hypermetabolism. Significant bilateral hypometabolism is noted in the lateral and medial prefrontal lobes, posterior cingulate gyrus, precuneus, inferior parietal lobes, and lateral occipital regions, including the primary visual cortex. In contrast, prominent focal hypermetabolism is demonstrated in the bilateral medial temporal lobes. This metabolic pattern—diffuse cortical hypometabolism with localized medial temporal hypermetabolism—is clinically relevant in the evaluation of autoimmune encephalitides, such as LGI1-antibody encephalitis, where PET can detect functional abnormalities even when structural MRI is unremarkable.

Two axial slices of an 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scan of the brain demonstrating a characteristic metabolic pattern. The primary visual finding is strong, focal hypermetabolism in the bilateral basal ganglia (caudate and putamen), represented by intense red and orange color mapping. In contrast, the surrounding cerebral cortex exhibits diffuse hypometabolism, visualized through a spectrum of yellow, green, and purple shades, indicating significantly lower glucose uptake compared to the basal ganglia. These metabolic findings are indicative of neurological or autoimmune processes, such as anti-GAD antibody-associated encephalitis or chorea-related conditions, where deep gray matter structures show disproportionately high activity against a background of cortical suppression.

Now let me get the remaining textbook content and fetch the images.

Reading File

Loading Image

I now have comprehensive data from both the textbook and recent literature. Let me also get the textbook figure and fetch the paraneoplastic limbic encephalitis image.

Loading Image

Here is a complete, structured reporting guide for FDG Brain PET/CT in Autoimmune Encephalitis (AIE).

FDG Brain PET/CT in Autoimmune Encephalitis - Reporting Guide

Why FDG PET is Important in AIE

FDG PET is superior to MRI for detecting AIE involvement:

PET detects abnormalities in 78-100% of AIE cases
MRI detects abnormalities in only 42-63% of cases
PET is particularly more sensitive than MRI in anti-NMDAR encephalitis
PET can be positive even when antibody results are pending or negative
FDG PET can be used for treatment response monitoring - abnormalities normalize with successful immunotherapy

(Bradley and Daroff's Neurology in Clinical Practice, p. 857)

Part 1: Systematic Approach - What to Look For

Step 1 - Pre-Report Checklist

Before starting, note:

Patient's age and sex (strongly guides differential; anti-NMDAR predominantly young women, LGI1 predominantly older men)
Clinical presentation: psychiatric symptoms, seizures, memory impairment, movement disorder, autonomic dysfunction, sleep disturbance
Serum sodium (hyponatremia is a red flag for LGI1)
Known antibody status if available (guides pattern recognition)
Time from symptom onset to PET (patterns are most distinct in the first 1-2 weeks; later imaging may show mixed or less specific patterns)

Step 2 - Technical Assessment

Patient preparation: Was the patient adequately fasted (>6h)? Blood glucose should ideally be <150-180 mg/dL; hyperglycemia causes FDG redistribution and artefactual cortical hypometabolism
Seizure activity: Was there recent seizure activity? Peri-ictal scans show local hypermetabolism that can mimic or exaggerate AIE patterns - check EEG timing
Sedation: Some patients with AIE are sedated/intubated; this can cause diffuse cortical hypometabolism and confound interpretation
CT attenuation correction: Check for metal artefacts affecting PET quantification

Step 3 - Brain Regions to Systematically Evaluate

Go through each region and describe whether uptake is normal, hypometabolic, or hypermetabolic:

Region	What to Look For
Medial temporal lobes (hippocampus, amygdala)	Hypermetabolism (most common finding in AIE) - often asymmetric
Basal ganglia (caudate, putamen)	Hypermetabolism - very characteristic, especially in LGI1
Frontal lobes (prefrontal cortex)	Hypometabolism in anti-NMDAR; hypermetabolism in some
Parietal lobes (inferior parietal, precuneus)	Hypometabolism, especially in anti-NMDAR
Occipital lobes	Hypometabolism, especially "wedge-shaped" in anti-NMDAR
Posterior cingulate / precuneus	Hypometabolism (can mimic Alzheimer's pattern - deafferentation from temporal pathology)
Cerebellum	Hypermetabolism OR hypometabolism - present in ~70% of AIE cases
Thalamus/brainstem	Hypermetabolism can occur, note asymmetry
Insular cortex	Occasional involvement in limbic encephalitis

Key principle: Most AIE cases show a combination of focal hypermetabolism (limbic/subcortical) with background cortical hypometabolism.

Step 4 - Pattern Recognition

Three broad patterns seen across AIE:

Isolated hypermetabolism (~41% of cases) - typically medial temporal + basal ganglia
Isolated hypometabolism (~41% of cases) - typically cortical, frontal/parietal/occipital
Combined (~18%) - hypermetabolic limbic regions with hypometabolic cortex

Part 2: Specific Antibody Subtypes and Their FDG PET Patterns

1. Anti-NMDAR Encephalitis

Who: Young women (mean age ~25 years), often with ovarian teratoma (up to 50% of women <45 yrs) Clinical: Acute psychiatric onset → memory loss → reduced consciousness → movement disorders → autonomic instability → seizures

FDG PET Pattern:

Frontotemporal hypermetabolism (early/active phase)
Parietal and occipital hypometabolism - this is the signature finding
"Wedge-shaped" occipital hypometabolism - characteristic and more severe/frequent than other AIE subtypes
Diffuse cortical hypometabolism - affects both prefrontal AND posterior associative cortices simultaneously (the only subtype to do this in a majority of patients)
"Anteroposterior gradient" - relatively higher frontal vs. posterior metabolism
Findings are often heterogeneous and don't always fit one neat pattern
MRI is frequently normal - PET is especially valuable here
Patterns resolve completely with successful treatment, even after prolonged illness

Quick summary: Widespread cortical hypometabolism, especially occipital + parietal, with relative frontal hypermetabolism or a mixed picture.

2. Anti-LGI1 Encephalitis

Who: Older males (mean age ~57 years), associated with thymoma in <20% Clinical: Faciobrachial dystonic seizures (FBDS) - pathognomonic, cognitive decline, hyponatremia, sleep disturbance, psychiatric symptoms

FDG PET Pattern:

Basal ganglia (striatal) hypermetabolism - present in virtually ALL cases (87-100%)
Medial temporal lobe (MTL) hypermetabolism - present in ~75-82% of cases, often bilateral
Cerebellar hypermetabolism
Frontal hypometabolism
Findings are often asymmetric (differential expression of LGI1 receptor)
Striatal hypermetabolism may correspond to the substrate for FBDS

Quick summary: Bilateral (often asymmetric) basal ganglia + medial temporal hypermetabolism with frontal hypometabolism. The most "classic" pattern in AIE.

This is the typical pattern shown in the SSP map below:

FDG PET SSP map showing bilateral medial temporal hypermetabolism and cortical hypometabolism in LGI1 autoimmune encephalitis

SSP PET map (top) and Z-score map (bottom): bilateral medial temporal hypermetabolism (warm colors) with prefrontal and posterior cortical hypometabolism (blue) - characteristic of LGI1-antibody encephalitis

3. Anti-CASPR2 Encephalitis

Who: Middle-aged adults, male predominance; associated with thymoma Clinical: Morvan syndrome (neuromyotonia + encephalopathy), limbic encephalitis, severe autonomic dysfunction, insomnia, neuropathic pain; seizures less common than LGI1

FDG PET Pattern:

MTL hypermetabolism - most frequent, present in virtually all (100%) CASPR2 cases
Basal ganglia hypermetabolism (100%)
Bilateral occipital hypometabolism (75%) - more frequent than in LGI1 or NMDAR
"Anteroposterior gradient" similar to anti-NMDAR
Cerebellar hypometabolism can occur

Quick summary: MTL + basal ganglia hypermetabolism (like LGI1) but with prominent occipital hypometabolism.

4. Anti-GABA-B Receptor Encephalitis

Who: Middle-aged to elderly, strongly associated with SCLC (50%) and other neuroendocrine tumors Clinical: Refractory seizures (often the presenting feature), limbic encephalitis, memory loss

FDG PET Pattern:

Bilateral hippocampal/amygdala hypermetabolism - significantly elevated (higher SUVs than other AIE subtypes)
Temporal lobe hypermetabolism
Left supramarginal gyrus and right parietal lobe hypometabolism
Pattern overlaps with other limbic encephalitides but hippocampal uptake is characteristically intense

Quick summary: Prominent bilateral hippocampal hypermetabolism, often with parietal hypometabolism.

5. Anti-GABA-A Receptor Encephalitis

Who: Rare, associated with SCLC/neuroendocrine tumors in ~50% Clinical: Refractory multifocal seizures, status epilepticus, encephalopathy

FDG PET Pattern:

Variable, often multifocal hypermetabolism correlating with seizure foci
Peri-ictal scans can be misleading - confirm with EEG timing
Cortical and subcortical hypermetabolism may be widespread

6. Anti-AMPA Receptor Encephalitis

Who: Middle-aged women, associated with lung/breast cancer or thymoma (~70%) Clinical: Limbic encephalitis with prominent psychiatric features, memory loss

FDG PET Pattern:

Limbic (MTL) hypermetabolism
Pattern similar to other limbic encephalitides
Limited specific data due to rarity

7. Anti-GAD65 Encephalitis

Who: Younger women, NOT commonly paraneoplastic; often with other autoimmune conditions (T1DM, thyroid disease) Clinical: Limbic encephalitis, cerebellar ataxia, stiff-person syndrome; often more chronic

FDG PET Pattern:

MTL hypermetabolism (54% of cases - lower than LGI1/CASPR2)
Striatal hypermetabolism (~10%)
Cortical hypometabolism (~35%)
Cerebellar hypometabolism - particularly in GAD-associated cerebellar ataxia
Temporal hypometabolism can occur
Generally fewer abnormalities on PET than LGI1 or NMDAR

Quick summary: Less dramatic PET abnormalities; MTL hypermetabolism + cerebellar changes.

8. Paraneoplastic Limbic Encephalitis (Anti-Hu, Anti-Ma2 - Intracellular antibodies)

Who: Anti-Hu - older adults, predominantly SCLC; Anti-Ma2 - younger men, testicular tumors Clinical: Classic limbic encephalitis syndrome

FDG PET Pattern:

Prominent, often striking bilateral mesiotemporal hypermetabolism - more consistently present than with surface antibody AIE
Striatal and cerebellar hypermetabolism possible
Association cortex hypometabolism (posterior cingulate, precuneus, frontal)
This is the pattern shown in the textbook figure below:

Paraneoplastic limbic encephalitis FDG PET showing bilateral mesiotemporal hypermetabolism with whole-body PET CT showing primary lung tumor

Paraneoplastic limbic encephalitis in anti-Hu positive SCLC: bright bilateral mesiotemporal hypermetabolism (arrows) on brain PET; whole-body PET/CT showing the primary right upper lobe nodule and mediastinal node (from Bradley & Daroff's Neurology)

Important distinction: Intracellular antibody paraneoplastic LE tends to show mesiotemporal hypermetabolism more consistently than surface antibody encephalitis. Whole-body PET/CT is mandatory to find the primary tumor.

Part 3: Quick Reference Summary Table

AIE Subtype	Hypermetabolic	Hypometabolic	Key Feature
Anti-NMDAR	Frontotemporal (variable)	Parietal, occipital (diffuse), posterior cingulate	Diffuse cortical hypometabolism, "wedge-shaped" occipital
Anti-LGI1	Basal ganglia, MTL (asymmetric)	Frontal	BG hypermetabolism is hallmark; asymmetry
Anti-CASPR2	MTL, basal ganglia	Bilateral occipital	MTL + BG + occipital hypometabolism
Anti-GABA-B	Bilateral hippocampus (intense), temporal	Parietal	High hippocampal SUV
Anti-GABA-A	Multifocal (seizure-related)	Variable	Correlate with EEG
Anti-GAD65	MTL (mild-moderate)	Cerebellar, temporal	Fewer findings; cerebellar involvement
Paraneoplastic (Hu/Ma2)	Bilateral MTL (intense), striatum	Association cortex	Most consistent MTL hypermetabolism

Part 4: The CT Component

Don't forget the CT:

Low-dose CT for attenuation correction - check for major structural abnormalities (mass, stroke, atrophy)
Diagnostic CT: Look for evidence of primary malignancy (especially SCLC in older patients) - pulmonary nodule, mediastinal nodes
Intracranial CT is often normal in AIE
Atrophy may develop in chronic or untreated cases

Part 5: Reporting Template

A practical structure for your report:

1. Indication: e.g., "Known/suspected autoimmune encephalitis with subacute neuropsychiatric symptoms and positive anti-LGI1 antibodies"

2. Technique: FDG dose, uptake time, blood glucose at time of injection, scan parameters

3. Brain PET findings (go region by region):

Medial temporal lobes (L/R): hypermetabolic / hypometabolic / normal
Basal ganglia (caudate/putamen): hypermetabolic / normal
Frontal lobes: hypometabolic / normal
Parietal lobes: hypometabolic / normal
Occipital lobes: hypometabolic / normal
Posterior cingulate/precuneus: hypometabolic / normal
Cerebellum: normal / hypermetabolic / hypometabolic
Thalamus/brainstem: normal / abnormal

4. CT findings: Structural brain / extracranial (tumor screen)

5. Comparison with prior: Note interval change with treatment

6. Pattern impression: "The overall metabolic pattern is most consistent with limbic encephalitis, demonstrating bilateral medial temporal and basal ganglia hypermetabolism with frontal hypometabolism. In the clinical context of anti-LGI1 antibody positivity, these findings support active limbic encephalitis."

7. Differential: Even in antibody-positive cases, note whether pattern fits or raises alternative considerations (e.g., epileptic focus, neurodegenerative disease)

Part 6: Pitfalls and Tips

Peri-ictal scans: Seizure activity causes local hypermetabolism - always check EEG and clinical timing. If patient had a seizure within hours of scan, interpret hypermetabolic foci cautiously
"Recovering" phase: Mesiotemporal hypermetabolism may convert to hypometabolism after the acute phase, indicating irreversible post-inflammatory damage - not treatment failure
Seronegative AIE: PET is still frequently abnormal (93% in one series) and the pattern (frontal/temporal hypermetabolism) can aid diagnosis when antibodies are negative
Posterior cingulate hypometabolism: Can mimic Alzheimer's disease due to deafferentation from temporal lobe pathology - always correlate with clinical context
Voxel-based analysis (SSP/SPM): More sensitive than visual reading alone, especially for detecting extra-limbic hypermetabolism in LGI1 and CASPR2; use when available
Follow-up PET: Normalization of PET correlates with clinical improvement (mRS improvement) and can confirm treatment response

Sources: Bradley & Daroff's Neurology in Clinical Practice, p. 856-857; FDG-PET in AE - PMC 2023; Brain Metabolic Alterations in AE - MDPI 2023; FDG-PET Imaging Patterns in AE - MDPI 2020

what is meant by anterior posterior gradient?

The "anteroposterior gradient" on FDG PET refers to a pattern where the front of the brain (frontal lobes) has relatively higher metabolism compared to the back of the brain (parietal and occipital lobes), which are hypometabolic. Normally, metabolism is relatively uniform across the cortex; in this pattern, there is a visible front-to-back mismatch.

Searching sources...

Finding Sources

Searching Images

FDG PET anteroposterior gradient anti-NMDA encephalitis frontal hypermetabolism occipital hypometabolism

No library hits, so I'll answer directly from the research already in context from the previous turn plus my knowledge - this is well covered.

Anteroposterior Gradient on FDG PET

In normal brain FDG PET, glucose metabolism is relatively symmetric and evenly distributed across the cortex, with the highest uptake in the posterior cortices (visual cortex, posterior cingulate, parietal association areas) - these regions are tonically active even at rest.

The anteroposterior gradient describes a reversal or disruption of this normal pattern:

FRONT (Frontal)         -->    BACK (Parietal/Occipital)
Higher metabolism              Lower metabolism
Relatively "hot"               Relatively "cold"

This is the opposite of what you'd expect in a normal brain, and also the opposite of what you see in Alzheimer's disease (where the posterior regions drop out first while frontal is relatively preserved).

Why It Happens in Anti-NMDAR Encephalitis

The NMDA receptor is expressed diffusely across the cortex but is particularly important in parieto-occipital association areas and the default mode network. When anti-NMDA antibodies block these receptors:

Posterior cortex (parietal, occipital, posterior cingulate, precuneus) loses its normal resting activity → hypometabolism
Frontal lobes are relatively spared or may even show increased activity due to disinhibition of frontal circuits → relatively hypermetabolic or normal-appearing

The net visual effect on a PET scan is:

Frontal lobes appear warm/preserved
Parietal and occipital lobes appear cold/suppressed
There is a visible step-change from front to back - this is the "gradient"

How to Recognise It on a Scan

On axial slices at cortical level:

The anterior cortex (frontal) will appear orange/red relative to the posterior cortex
The parietal and occipital cortex will appear green/blue (hypometabolic)
On SSP surface projections it is very clear - the posterior surfaces are washed out compared to the anterior surfaces

On the Z-score maps (comparison to normals): you'll see negative Z-scores (blue) concentrated posteriorly while the frontal cortex sits near zero or positive.

Which AIE Subtypes Show This Pattern?

Subtype	Anteroposterior Gradient
Anti-NMDAR	Yes - classic, most prominent and diffuse
Anti-CASPR2	Yes - described in all 4 patients in one series
Anti-LGI1	Less prominent; pattern is more about basal ganglia + MTL hypermetabolism
GAD65 / GABA-B	Not a defining feature

Clinical Significance

It is not pathognomonic of anti-NMDAR encephalitis alone - CASPR2 can show it too
The severity of the gradient correlates with clinical severity - more widespread posterior hypometabolism = more severe disease
It resolves with successful treatment, even in prolonged cases - making it a useful treatment response marker
Do not confuse it with Alzheimer's disease (AD also shows posterior hypometabolism, but in AD the frontal lobes are usually also eventually involved, and the clinical context is completely different - gradual memory loss vs acute neuropsychiatric presentation)

Simple Way to Remember It

In anti-NMDAR encephalitis, the brain is "front-heavy" on FDG PET - the frontal lobe lights up relatively more, while the parietal and occipital lobes go quiet. Front is hot, back is cold - that slope from front to back is the anteroposterior gradient.

what is limbic encephalitis?

Limbic encephalitis (LE) is inflammation of the limbic system - the brain structures involved in memory, emotion, and behaviour (hippocampus, amygdala, cingulate cortex, insula). It presents subacutely with memory loss, psychiatric symptoms, and seizures, and can be autoimmune or paraneoplastic in origin.

Searching sources...

Finding Sources

Searching the Web

limbic encephalitis definition causes clinical features diagnosis treatment 2024

Good hits. Let me pull the dedicated textbook sections in parallel.

Reading File

Searching Images

limbic encephalitis MRI hippocampus T2 FLAIR hyperintensity medial temporal

This diagnostic image set consists of four MRI brain sequences—(a) Coronal T2, (b) Axial T2-FLAIR, (c) Apparent Diffusion Coefficient (ADC) map, and (d) Coronal T1 post-contrast—demonstrating characteristic findings of medial temporal lobe encephalitis. Yellow arrows across all sequences highlight pathology in the left hippocampus and medial temporal lobe. The Coronal T2 and Axial FLAIR images show abnormal high signal intensity and mild swelling of the hippocampus and parahippocampal gyrus. The ADC map reveals facilitated diffusion (hyperintensity) in the corresponding region, indicating vasogenic edema rather than acute infarction. The T1 post-contrast image displays patchy parenchymal enhancement within the affected medial temporal structures, suggesting blood-brain barrier breakdown or inflammation. These findings are clinically significant for diagnosing encephalitis patterns, such as those associated with viral infections (including SARS-CoV-2) or autoimmune etiologies, targeting the limbic system.

This composite diagnostic image displays neuroimaging findings in a patient with anti-LGI1 limbic encephalitis. Panels A and B are coronal T2-weighted Fluid-Attenuated Inversion Recovery (T2W FLAIR) MRI scans. Panel A demonstrates abnormal hyperintensities within the left medial temporal lobe and hippocampus, while Panel B reveals moderate hippocampal atrophy, classified as Medial Temporal Lobe Atrophy (MTA) score 3. Panels C and D provide functional assessment via 18F-FDG PET/CT. Panel C (axial view) shows hypometabolism, indicated by a partial absence of radioactivity (cool blue tones) in the left medial temporal cortex and hippocampus compared to the contralateral side. Panel D (coronal view) highlights markedly reduced tracer uptake in the head of the left caudate nucleus. Collectively, these images illustrate the correlation between structural MRI changes (hyperintensity and atrophy) and functional PET deficits (hypometabolism) characteristic of autoimmune limbic encephalitis involving the medial temporal lobes and basal ganglia.

**Imaging Modality:** Magnetic Resonance Imaging (MRI), axial section.

Excellent - rich content from both the neurology and radiology textbooks, plus images. Here is a comprehensive answer:

Limbic Encephalitis

What Is It?

Limbic encephalitis (LE) is inflammation of the limbic system - the group of brain structures that control memory, emotion, behaviour, and seizure activity. It presents with a characteristic triad:

Memory loss + Psychiatric/behavioural change + Seizures - developing subacutely over days to weeks

The word "limbic" comes from the Latin limbus (border) - the limbic system forms a ring around the inner border of the cortex. The structures most affected are:

Hippocampus - memory consolidation
Amygdala - emotion and fear responses
Parahippocampal gyrus and entorhinal cortex
Cingulate gyrus (especially anterior cingulate)
Hypothalamus (in some subtypes)
Insula

The Limbic System - Why These Symptoms?

Structure Inflamed	Symptom Produced
Hippocampus	Short-term memory loss, anterograde amnesia
Amygdala	Fear, anxiety, agitation, personality change
Parahippocampal cortex	Spatial disorientation, complex partial seizures
Cingulate gyrus	Behavioural disturbance, emotional dysregulation
Hypothalamus	Hyperthermia, autonomic instability, hypersomnia

Causes - Two Main Categories

1. Paraneoplastic Limbic Encephalitis (antibodies against INTRACELLULAR antigens)

Triggered by a remote tumor - the immune system attacks the tumor but cross-reacts with limbic neurons.

Antibody	Associated Tumor	Key Feature
Anti-Hu	SCLC (most common)	Often part of widespread encephalomyelitis
Anti-Ma2	Testicular germ cell tumor (young men)	Upper brainstem involvement, vertical gaze palsy
Anti-CV2/CRMP5	SCLC, thymoma	Also causes chorea, cerebellar ataxia, optic neuritis
Anti-amphiphysin	Breast cancer, SCLC	Can coexist with stiff-person syndrome

These are T-cell mediated (intracellular targets are not accessible to antibodies)
Poor response to immunotherapy - treatment is directed at the tumor
Irreversible neuronal damage is common
Only ~30% of Ma2-positive patients improve with treatment

2. Autoimmune Limbic Encephalitis (antibodies against CELL SURFACE antigens)

The antibodies directly attack receptors or ion channels on the neuronal surface. These are potentially reversible with immunotherapy.

Antibody	Key Features
Anti-LGI1	Older men, FBDS (faciobrachial dystonic seizures), hyponatremia
Anti-CASPR2	Morvan syndrome, autonomic dysfunction, neuromyotonia
Anti-GABA-B	Refractory seizures, SCLC association
Anti-AMPA	Prominent psychiatric features, lung/breast cancer
Anti-NMDAR	Young women, ovarian teratoma, psychiatric onset (technically wider than just limbic)
Anti-GAD65	Non-paraneoplastic, associated with T1DM/autoimmune disorders

(Bradley & Daroff's Neurology in Clinical Practice)

Clinical Features

Core Triad

Subacute onset (days to ~12 weeks) of:
Memory impairment - short-term memory loss is hallmark; long-term memory relatively preserved initially
Neuropsychiatric symptoms - anxiety, depression, agitation, personality change, psychosis, confusion
- Seizures - usually complex partial (temporal lobe type); may be the presenting feature (especially in LGI1)

Additional Features (vary by subtype)

Sleep disturbance (insomnia, hypersomnia, REM behaviour disorder)
Autonomic dysfunction (tachycardia, blood pressure swings, hyperhidrosis)
Movement disorders (dyskinesias, faciobrachial dystonic seizures in LGI1)
Decreased level of consciousness in severe cases
Hyponatremia (particularly in LGI1)

Diagnostic Criteria (Graus et al., Lancet Neurol 2016)

All 4 of the following must be present for definite autoimmune limbic encephalitis:

Subacute onset (<3 months) of working memory deficits, seizures, or psychiatric symptoms suggesting limbic involvement
Bilateral brain abnormalities on T2-weighted MRI, highly restricted to medial temporal lobes
At least one of:
- CSF pleocytosis (>5 WBC/mm³)
- EEG with epileptic or slow-wave activity in the temporal lobes
Reasonable exclusion of alternative causes

(Note: If antibodies against cell-surface antigens are detected, diagnosis can be made even if not all criteria are met)

Investigations

MRI Brain

T2/FLAIR: Bilateral (or unilateral) medial temporal hyperintensity and swelling - hippocampus is the epicenter
T1: May show hypointensity in the medial temporal lobes
DWI: Facilitated diffusion (vasogenic edema) - helps distinguish from HSV encephalitis which shows restricted diffusion
Contrast: Patchy enhancement may occur (blood-brain barrier breakdown)
Normal MRI does NOT exclude LE - especially early or in anti-NMDAR encephalitis

Here is a characteristic MRI appearance:

MRI brain showing limbic encephalitis with left hippocampal T2 hyperintensity, swelling, and patchy enhancement on T1 post-contrast

Coronal T2, Axial FLAIR, ADC map, and T1 post-contrast: left hippocampal hyperintensity, swelling, facilitated diffusion (vasogenic), and patchy enhancement - classic limbic encephalitis pattern

And in LGI1 encephalitis with combined MRI and FDG PET correlation:

Anti-LGI1 encephalitis: Left MTL hyperintensity on FLAIR (A), hippocampal atrophy MTA grade 3 (B), left medial temporal hypometabolism on FDG PET axial (C), and reduced caudate uptake on coronal PET (D)

FDG PET

Abnormal in 78-100% of cases (vs 42-63% for MRI)
Medial temporal hypermetabolism is the hallmark in acute LE
Striatal hypermetabolism, cortical hypometabolism (pattern varies by antibody - see previous answer)

CSF Analysis

Lymphocytic pleocytosis (usually mild, 10-100 cells/mm³)
Mildly elevated protein
Normal glucose
Oligoclonal bands may be present

Antibody Testing

Serum AND CSF - some antibodies are detected better in CSF (e.g., anti-NMDAR)
Panel should include: NMDAR, LGI1, CASPR2, GABA-B, AMPA, GABA-A, DPPX, GAD65
Paraneoplastic panel: Hu, Ma2, CV2/CRMP5, Ri, amphiphysin, Yo

EEG

Temporal lobe epileptiform discharges
Slowing over temporal regions
Helps localise and characterise seizure activity

Whole-Body FDG PET/CT

Mandatory in ALL cases - screen for occult malignancy
Especially important in Hu/Ma2 positive cases and GABA-B (high tumor frequency)

Key Differential Diagnoses

Condition	How to Differentiate
HSV encephalitis	Often unilateral, involves insula + orbitofrontal cortex, restricted diffusion on DWI, fever, PCR positive
Creutzfeldt-Jakob disease	Rapidly progressive, "cortical ribboning" on DWI, EEG triphasic waves
Alzheimer's disease	Gradual onset over years, not subacute; posterior cortical hypometabolism on PET
Psychiatric illness (first-break psychosis)	Normal MRI, EEG, CSF - always exclude LE in new-onset psychosis
Status epilepticus	Peri-ictal MRI changes in temporal lobes can mimic LE - correlate with EEG

Treatment

Immunotherapy (for autoimmune/surface-antibody LE)

First line:

IV methylprednisolone (1g/day x 5 days)
IV immunoglobulin (IVIG, 2g/kg over 5 days)
Plasma exchange (PLEX)

Second line (if no response within 2-4 weeks):

Rituximab
Mycophenolate mofetil
Azathioprine

For paraneoplastic LE:

Treat the underlying tumor (first priority)
Immunotherapy as adjunct
Response is poor compared to surface-antibody LE

Symptomatic

Anti-seizure medications (note: FBDS in LGI1 respond poorly to ASMs but well to immunotherapy)
Psychiatric support/behavioural management

Prognosis

Surface antibody LE (LGI1, CASPR2, GABA-B, NMDAR): Good prognosis with early immunotherapy; reversible in most cases; MRI and PET changes normalize with treatment
Intracellular antibody paraneoplastic LE (Hu, Ma2): Poor neurological prognosis; irreversible damage; depends on tumor treatment
Chronic hippocampal atrophy and memory impairment can remain even after treatment

Sources: Bradley & Daroff's Neurology in Clinical Practice, pp. 2509-2530; Grainger & Allison's Diagnostic Radiology, p. 1492; Graus et al. Lancet Neurol 2016; IPA Online - Limbic Encephalitis

What is the difference between paraneoplastic vs autoimmune limbic encephalitis?

The core difference: paraneoplastic LE is triggered by a remote tumor, while autoimmune LE has no underlying cancer (or a much weaker tumor association). The antibody targets also differ fundamentally - intracellular in paraneoplastic vs cell-surface in autoimmune - which drives completely different mechanisms, treatment responses, and prognoses.

Searching sources...

Finding Sources

Good hits. Let me read the key textbook sections.

Reading File

Excellent - Harrison's has a very detailed mechanistic diagram. Let me fetch it.

Loading Image

Perfect - the Harrison's figure is exactly what's needed to illustrate this difference visually. Here is a complete answer:

Paraneoplastic vs. Autoimmune Limbic Encephalitis

The single most important conceptual divide is where the antibody target is located - intracellular (paraneoplastic) vs. cell surface (autoimmune). Everything else - the mechanism, the tumor association, the treatment response, and the prognosis - flows from this one difference.

The Fundamental Mechanism - Visualised

Harrison's Figure 99-1: Left panel shows encephalitis associated with intracellular antigens - cytotoxic T cells directly attack neurons, antibodies cannot reach the target; Right panel shows encephalitis associated with cell-surface antigens - antibodies directly bind and disrupt surface receptors at the synapse. Histology shows T-cell infiltration and neuronal loss in paraneoplastic vs plasma cell deposits and IgG deposition in autoimmune.

Harrison's Principles of Internal Medicine 22e, Fig 99-1: Left (A,C,E,G,H) = intracellular antigen encephalitis (paraneoplastic). Right (B,D,F,I,J) = cell-surface antigen encephalitis (autoimmune). Notice on the live neuron test (E vs F): anti-Hu antibodies cannot label the live neuron (no access), while anti-NMDAR antibodies light up the entire dendritic surface.

Side-by-Side Comparison

Feature	Paraneoplastic LE	Autoimmune LE
Antibody target location	Intracellular (inside the neuron - nucleus, cytoplasm)	Cell surface / synaptic (on the neuronal membrane, accessible)
Example antibodies	Anti-Hu, Anti-Ma2, Anti-CV2/CRMP5, Anti-amphiphysin, Anti-Yo	Anti-NMDAR, Anti-LGI1, Anti-CASPR2, Anti-GABA-B, Anti-AMPA, Anti-GAD65
Tumor association	Always - by definition, the tumor triggers the immune response	Variable - may or may not have a tumor
Common tumors	SCLC (Hu), Testicular germ cell (Ma2), Thymoma (CV2), Ovarian teratoma	SCLC (GABA-B ~50%), Thymoma (LGI1 <20%), Ovarian teratoma (NMDAR ~50% females)
Primary immune mechanism	Cytotoxic T-cell mediated - T cells directly kill neurons; antibodies are biomarkers, NOT the effectors	Antibody-mediated - antibodies directly bind, crosslink, internalize, or block receptors → receptor dysfunction
Can antibodies cause damage?	No - the intracellular antigen is inaccessible to circulating antibodies	Yes - antibodies directly alter receptor structure and function
Neuropathology	Neuronal loss + dense T-cell infiltrates (perforin/granzyme mechanisms)	Moderate inflammation, plasma cells, IgG deposits, minimal neuronal loss
Reversibility	Largely irreversible - neurons are destroyed by T cells; structural damage persists	Largely reversible - antibody removal restores receptor function; neurons mostly intact
Response to immunotherapy	Poor - removing antibodies doesn't stop T-cell damage; ~1/3 improve with tumor treatment	Good - steroids, IVIG, plasma exchange, rituximab are effective
Treatment priority	Treat the tumor first - this is the definitive treatment	Immunotherapy first - tumor treatment secondary if applicable
Prognosis	Generally poor; significant residual neurological disability common	Generally good with early treatment; full recovery possible
Relapse	Less common (tumor drives the immune response; treat the tumor, stop the trigger)	Can relapse, especially if no tumor found or maintenance immunotherapy stopped

Why Antibodies Are Markers vs. Effectors

In paraneoplastic LE, the sequence is:

Tumor expresses neuronal proteins (e.g., Hu protein in SCLC)
Immune system mounts a T-cell response against the tumor
Those same T cells cross-react with neurons expressing the same protein
T cells kill neurons directly (perforin/granzyme pathway)
The antibodies (Anti-Hu etc.) are produced alongside but cannot reach the intracellular epitope - they are diagnostic biomarkers, not the weapon

In autoimmune LE, the sequence is:

Antibodies are produced against a surface antigen (often a receptor)
Antibodies cross the blood-brain barrier and bind directly to the receptor
The receptor is internalized, blocked, or structurally altered
Synaptic transmission is disrupted → symptoms
Remove the antibodies (plasma exchange, IVIG) → receptor function recovers → symptoms improve

(Harrison's Principles of Internal Medicine 22e, p. 788-789; Bradley & Daroff's Neurology, p. 1265)

The "Gray Zone" - Overlap and Complexity

Some points that blur the line:

Surface antibody LE CAN have a tumor - GABA-B has SCLC in ~50%, anti-NMDAR has ovarian teratoma in up to 50% of young women. So "autoimmune LE" is not always tumor-free - the key distinction is the antibody target location and mechanism, not strictly whether a tumor is present.
GAD65 is technically an intracellular antibody (GAD65 is inside the vesicle) but behaves more like surface-antibody disease - partially responds to immunotherapy, lower tumor association. It is a borderline case.
Immune checkpoint inhibitor drugs (anti-PD1, anti-CTLA4) used in cancer treatment can unmask or trigger both types - classical paraneoplastic antibodies (Hu) and cell-surface antibodies can emerge after immunotherapy.

MRI Comparison

Harrison's Figure 99-2: Four MRI brain FLAIR images - A shows limbic encephalitis with bilateral medial temporal hyperintensity (applies to both paraneoplastic and autoimmune LE); B shows anti-NMDAR encephalitis with often normal or very subtle MRI; C shows anti-GABA-B encephalitis with extensive cortical-subcortical FLAIR changes; D shows MOG-antibody cortical encephalitis with extensive cortical signal in a child.

Harrison's 22e, Fig 99-2: (A) Classic limbic encephalitis - bilateral MTL FLAIR hyperintensity, seen in both paraneoplastic and autoimmune LE. (B) Anti-NMDAR - often normal or subtle. (C) Anti-GABA-B - extensive cortical-subcortical changes. (D) MOG-antibody cortical encephalitis.

Practical Clinical Clues to Tell Them Apart at the Bedside

Clue	Suggests Paraneoplastic	Suggests Autoimmune
Age	Older (Hu, CV2 - middle-aged to elderly)	Younger (NMDAR - young women; LGI1 - older men but responds)
Known cancer / smoking history	Strong pointer	Less likely
Rapid deterioration, not responding to immunotherapy	Paraneoplastic (T-cell damage ongoing)	Autoimmune would usually show some response
Multifocal neurological deficits (cerebellar + limbic + PNS)	Paraneoplastic encephalomyelitis (Hu)	Less typical
Prominent psychiatric onset	Less typical	Anti-NMDAR (very common)
Faciobrachial dystonic seizures	Not typical	Anti-LGI1 (pathognomonic)
Autonomic dysfunction + neuromyotonia	Less typical	Anti-CASPR2 (Morvan)
Hyponatremia	Not specific	LGI1 (common)
Whole-body PET shows avid primary tumor	Strong pointer	May be incidental
CSF: heavy pleocytosis, T-cell dominant	Paraneoplastic	Autoimmune usually milder pleocytosis

Summary in One Sentence Each

Paraneoplastic LE: A tumor expresses neuronal proteins, T cells attack the tumor and cross-react with neurons, causing irreversible neuronal death - antibodies are bystanders, not the cause.

Autoimmune LE: Antibodies directly bind surface receptors on neurons and disrupt their function - neurons survive if antibodies are removed promptly, making this a treatable and reversible condition.

Sources: Harrison's Principles of Internal Medicine 22e, pp. 788-789; Bradley & Daroff's Neurology in Clinical Practice, pp. 2514-2530, 2891

show all pet images of AIE

Let me search for all available FDG PET images of autoimmune encephalitis subtypes.

Searching Images

FDG PET brain autoimmune encephalitis anti-NMDA receptor hypermetabolism hypometabolism

This diagnostic image set displays a longitudinal comparison of [18F]-FDG-PET and matching MRI-T2-FLAIR axial brain scans from three patients with anti-NMDA receptor (NMDAR) encephalitis. The panels are organized by patient (1, 2, and 3) across three time points: T0 (onset), T6 (6 months), and T18 (18 months). The visual content is divided into two columns: the Medial Temporal Lobe (left) and the Temporo-parieto-occipital region (right). Key findings include: (1) Patient 1 shows bilateral hypometabolism in lateral temporal and posterior parietal lobes at T0, peaking at T6 before resolving by T18. (2) Patient 2 exhibits bilateral occipital hypometabolism at T0 (white arrow) and transient basal ganglia hypermetabolism relative to cortical hypometabolism at T6. (3) Patient 3 demonstrates right-sided medial temporal lobe hypometabolism on PET (yellow arrow) corresponding to hyperintensity on MRI-FLAIR (yellow rectangle) at T0, with resolution at subsequent time points. The image illustrates the correlation between functional metabolic changes on PET and structural findings on MRI in autoimmune encephalitis progression and recovery.

Searching Images

FDG PET LGI1 CASPR2 limbic encephalitis basal ganglia medial temporal hypermetabolism

Searching Images

PET scan encephalitis striatum caudate putamen hypermetabolism cortical hypometabolism

Searching Images

paraneoplastic limbic encephalitis FDG PET mesiotemporal hypermetabolism whole body tumor

Finding Sources

Let me scan the textbook blocks for all PET image URLs and also fetch the NMDAR longitudinal image.

Reading File

Loading Image

Searching Images

FDG PET brain encephalitis surface projection SSP Z-score map temporal frontal occipital metabolism

Now let me fetch all the textbook PET images and also check for any more in the textbook blocks.

Reading File

Loading Image

Here are all the FDG PET images of AIE available, collected and annotated:

FDG PET Images in Autoimmune Encephalitis

Image 1 - Paraneoplastic Limbic Encephalitis (Anti-Hu / SCLC)

Paraneoplastic limbic encephalitis FDG PET: bright bilateral mesiotemporal hypermetabolism with arrows, plus whole-body PET CT showing right upper lobe lung nodule and mediastinal node

What you're seeing:

Top panel (brain PET): Striking bilateral mesiotemporal (hippocampal) hypermetabolism - the bright white/yellow foci marked by arrows. Mild left association cortex hypometabolism in the background.
Bottom panel (whole-body PET/CT): The primary SCLC - a 5mm spiculated right upper lobe nodule (low metabolic activity, circled) and a strongly FDG-avid mediastinal lymph node.
Subtype: Anti-Hu positive, 68-year-old male with paraneoplastic LE
Key point: Intracellular antibody subtypes show the most consistent and dramatic mesiotemporal hypermetabolism

(Bradley & Daroff's Neurology in Clinical Practice, Fig 42.23)

Image 2 - LGI1 Encephalitis: SSP Surface Projection + Z-Score Map

FDG PET SSP surface projection map (top) and Z-score map (bottom) in LGI1 autoimmune encephalitis: bilateral medial temporal and inferior temporal hypermetabolism with medial and lateral prefrontal and posterior cortical hypometabolism

What you're seeing:

Top row (SSP PET): Raw metabolic map. Red/orange = high uptake. The inferior surfaces (temporal) show warm activity; the medial surfaces (posterior cingulate/precuneus) show a blue dropout.
Bottom row (SSP Z-Score): Comparison to age-matched normals. Blue = significantly hypometabolic (Z < -2). Warm colors = hypermetabolic (Z > +2).
- Bilateral medial temporal and inferior temporal hypermetabolism (warm, seen on the inferior and medial projections)
- Prefrontal and posterior cortical hypometabolism (blue on lateral and medial surface views)
Subtype: LGI1 encephalitis in a 60-year-old male with seizures and memory impairment
Key point: SSP/Z-score maps are far more sensitive than visual axial slice reading alone

Image 3 - Axial FDG PET/CT: Basal Ganglia Hypermetabolism + Cortical Hypometabolism

Axial FDG PET/CT brain slices showing intense bilateral basal ganglia caudate and putamen hypermetabolism (red/pink) against background of diffuse cortical hypometabolism (green/blue)

What you're seeing:

Left slice (basal ganglia level): Intense bilateral caudate and putamen hypermetabolism - the deep red/pink foci in the center of the brain. Surrounding cortex is relatively cold (green/blue = hypometabolic).
Right slice (cortical level): Background cortical hypometabolism with a single area of relative left-sided preserved activity.
Subtype: Anti-GAD antibody encephalitis / autoimmune encephalitis with chorea-related presentation
Key point: Disproportionate deep grey matter (basal ganglia) hypermetabolism against suppressed cortex is a hallmark of both LGI1 and autoimmune chorea-encephalitis subtypes

Image 4 - Anti-NMDAR Encephalitis: Longitudinal FDG PET + MRI Comparison (3 Patients, 3 Time Points)

Longitudinal FDG PET and MRI FLAIR comparison in 3 patients with anti-NMDAR encephalitis at T0 onset, T6 months, T18 months showing bilateral occipital and parietal hypometabolism, basal ganglia relative hypermetabolism, and medial temporal changes that resolve with treatment

What you're seeing:

Layout: 3 patients (rows 1, 2, 3). Each row shows PET (top) and MRI FLAIR (bottom) at T0 (onset), T6 (6 months), T18 (18 months).
Left 3 columns = medial temporal lobe level; Right 3 columns = temporo-parieto-occipital level
Patient 1: Bilateral lateral temporal and posterior parietal hypometabolism at onset (T0), peaking at T6, resolving by T18 - MRI is normal throughout
Patient 2: Bilateral occipital hypometabolism at T0 (white arrow) - the anteroposterior gradient in action; basal ganglia relative hypermetabolism visible against cortical hypometabolism at T6
Patient 3: Right medial temporal hypometabolism on PET (yellow arrow) corresponding exactly to the FLAIR hyperintensity on MRI (yellow rectangle) at T0; both resolve by T18
Key points:
- Anti-NMDAR patterns are heterogeneous - some show posterior hypometabolism, some temporal, some mixed
- PET changes resolve with successful treatment - confirming the reversibility of surface-antibody LE
- MRI may be normal even when PET is clearly abnormal

Summary Reference: Which Pattern Goes with Which Subtype

Image	Subtype	Dominant PET Finding
Image 1	Paraneoplastic (Anti-Hu)	Bilateral MTL hypermetabolism
Image 2	Anti-LGI1	MTL + frontal hyper; posterior cortex hypo
Image 3	Anti-GAD / chorea-type AIE	Basal ganglia hyper + cortical hypo
Image 4	Anti-NMDAR	Occipital/parietal hypo + variable temporal; resolves with Rx

Create a quick reference PET pattern checklist for reporting each AIE subtype

Reading File

Good. I'll create a well-designed PDF checklist using reportlab with a clean clinical layout - colour-coded by AIE subtype, with checkboxes for each region.

Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace/aie-checklist

Running Command

mkdir -p /tmp/workspace/aie-checklist && cat > /tmp/workspace/aie-checklist/generate_checklist.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.units import cm, mm from reportlab.platypus import (SimpleDocTemplate, Table, TableStyle, Paragraph, Spacer, HRFlowable) from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_RIGHT from reportlab.platypus import KeepTogether from reportlab.graphics.shapes import Drawing, Rect, String, Line from reportlab.graphics import renderPDF W, H = A4 # 595.27 x 841.89 pts # ── Color palette ────────────────────────────────────────────────────────────── NAVY = colors.HexColor('#1A2E4A') STEEL = colors.HexColor('#2C5F8A') TEAL = colors.HexColor('#1A7A7A') ORANGE = colors.HexColor('#E05A00') PURPLE = colors.HexColor('#5B2D8E') GREEN = colors.HexColor('#1A7A3A') CRIMSON = colors.HexColor('#8B0000') GOLD = colors.HexColor('#B8860B') SLATE = colors.HexColor('#4A5568') LIGHT_BG = colors.HexColor('#F0F4F8') WHITE = colors.white PALE_GOLD = colors.HexColor('#FFF8E7') PALE_TEAL = colors.HexColor('#E6F4F4') PALE_PURP = colors.HexColor('#F3EEFF') PALE_ORAN = colors.HexColor('#FFF0E6') PALE_CRIM = colors.HexColor('#FFF0F0') PALE_GREE = colors.HexColor('#EFF8F0') PALE_BLUE = colors.HexColor('#EEF4FF') PALE_NAVY = colors.HexColor('#E8EDF4') DIVIDER = colors.HexColor('#CBD5E0') styles = getSampleStyleSheet() def S(name, **kw): """Quick paragraph style factory""" base = styles['Normal'] ps = ParagraphStyle(name, parent=base, **kw) return ps title_style = S('Title', fontSize=16, fontName='Helvetica-Bold', textColor=NAVY, spaceAfter=2, leading=20) subtitle_style = S('Subtitle', fontSize=9, fontName='Helvetica', textColor=SLATE, spaceAfter=6, leading=12) section_hdr = S('SecHdr', fontSize=8.5, fontName='Helvetica-Bold', textColor=WHITE, spaceAfter=0, leading=11, alignment=TA_LEFT) body_sm = S('BodySm', fontSize=7.5, fontName='Helvetica', textColor=colors.black, leading=10) body_bold = S('BodyBold', fontSize=7.5, fontName='Helvetica-Bold', textColor=colors.black, leading=10) caption = S('Cap', fontSize=7, fontName='Helvetica-Oblique', textColor=SLATE, leading=9) check_style = S('Chk', fontSize=7.5, fontName='Helvetica', leading=10) footer_style = S('Ftr', fontSize=6.5, fontName='Helvetica-Oblique', textColor=SLATE, alignment=TA_CENTER) label_style = S('Lbl', fontSize=7, fontName='Helvetica-Bold', textColor=WHITE, leading=9, alignment=TA_CENTER) CHECKBOX = "☐" HYPER = "▲ HYPER" HYPO = "▼ HYPO" NORMAL = "– NORMAL" VAR = "~ VARIABLE" def cb(text, bold=False): st = body_bold if bold else body_sm return Paragraph(f"{CHECKBOX} {text}", st) def region_row(region, finding, note=""): icon = "" if "HYPER" in finding: icon = "🔴" elif "HYPO" in finding: icon = "🔵" elif "VARIABLE" in finding: icon = "🟡" else: icon = "⚪" note_txt = f" {note}" if note else "" return [Paragraph(f"{CHECKBOX} {region}", body_sm), Paragraph(f"{finding}{note_txt}", body_sm)] def make_subtype_table(title, color, pale, rows, clinical_note, abbrev): """Build one subtype block as a table""" # Header row header = Table( [[Paragraph(f" {abbrev}", label_style), Paragraph(f" {title}", section_hdr), Paragraph(f" {clinical_note}", caption)]], colWidths=[1.4*cm, 8.0*cm, 7.4*cm] ) header.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,0), color), ('VALIGN', (0,0), (-1,0), 'MIDDLE'), ('TOPPADDING', (0,0), (-1,0), 4), ('BOTTOMPADDING', (0,0), (-1,0), 4), ('LEFTPADDING', (0,0), (-1,0), 6), ('GRID', (0,0),(-1,0), 0.3, colors.white), ])) # Data rows data = [] for r in rows: data.append(r) tbl = Table(data, colWidths=[8.5*cm, 8.3*cm]) tbl.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,-1), pale), ('TOPPADDING', (0,0),(-1,-1), 3), ('BOTTOMPADDING', (0,0),(-1,-1), 3), ('LEFTPADDING', (0,0),(-1,-1), 8), ('RIGHTPADDING', (0,0),(-1,-1), 6), ('ROWBACKGROUNDS',(0,0),(-1,-1), [pale, colors.white]), ('GRID', (0,0),(-1,-1), 0.2, DIVIDER), ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ])) return KeepTogether([header, tbl, Spacer(1, 4)]) # ── Build document ───────────────────────────────────────────────────────────── doc = SimpleDocTemplate( '/tmp/workspace/aie-checklist/AIE_FDG_PET_Checklist.pdf', pagesize=A4, leftMargin=1.5*cm, rightMargin=1.5*cm, topMargin=1.5*cm, bottomMargin=1.5*cm, title="FDG PET/CT Brain – AIE Reporting Checklist", author="Orris Clinical AI" ) story = [] # ── TITLE BLOCK ──────────────────────────────────────────────────────────────── title_tbl = Table( [[Paragraph("FDG Brain PET/CT", title_style), Paragraph("Autoimmune Encephalitis – Reporting Checklist", subtitle_style)]], colWidths=[7*cm, 9.8*cm] ) title_tbl.setStyle(TableStyle([ ('VALIGN',(0,0),(-1,-1),'BOTTOM'), ('LEFTPADDING',(0,0),(-1,-1),0), ('BOTTOMPADDING',(0,0),(-1,-1),0), ])) story.append(title_tbl) story.append(HRFlowable(width='100%', thickness=2, color=NAVY, spaceAfter=6)) # ── PRE-REPORT CHECKLIST ─────────────────────────────────────────────────────── pre_hdr = Table([[Paragraph(" PRE-REPORT CHECKLIST", section_hdr)]], colWidths=[16.8*cm]) pre_hdr.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), NAVY), ('TOPPADDING',(0,0),(-1,-1), 4), ('BOTTOMPADDING',(0,0),(-1,-1), 4), ('LEFTPADDING',(0,0),(-1,-1), 6), ])) pre_data = [ [cb("Patient age & sex noted (guides differential)"), cb("Blood glucose at injection < 150–180 mg/dL")], [cb("Subacute clinical onset confirmed (days–weeks)"), cb("Recent seizure activity checked (EEG timing)")], [cb("Known antibody status recorded if available"), cb("Sedation / intubation noted (can cause diffuse hypometabolism)")], [cb("Time from symptom onset to scan noted"), cb("CT component reviewed for occult malignancy / structural lesion")], ] pre_tbl = Table(pre_data, colWidths=[8.4*cm, 8.4*cm]) pre_tbl.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), PALE_NAVY), ('TOPPADDING',(0,0),(-1,-1), 3), ('BOTTOMPADDING',(0,0),(-1,-1), 3), ('LEFTPADDING',(0,0),(-1,-1), 6), ('GRID',(0,0),(-1,-1), 0.2, DIVIDER), ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ('ROWBACKGROUNDS',(0,0),(-1,-1),[PALE_NAVY, colors.white]), ])) story.append(KeepTogether([pre_hdr, pre_tbl, Spacer(1,5)])) # ── LEGEND ───────────────────────────────────────────────────────────────────── legend_data = [[ Paragraph("🔴 ▲ HYPER = Hypermetabolism (increased FDG uptake vs background)", body_sm), Paragraph("🔵 ▼ HYPO = Hypometabolism (decreased FDG uptake vs background)", body_sm), Paragraph("🟡 ~ VARIABLE", body_sm), Paragraph("⚪ – NORMAL / not a defining feature", body_sm), ]] legend_tbl = Table(legend_data, colWidths=[5.2*cm, 5.2*cm, 2.8*cm, 3.6*cm]) legend_tbl.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), colors.HexColor('#F7FAFC')), ('BOX',(0,0),(-1,-1), 0.5, DIVIDER), ('TOPPADDING',(0,0),(-1,-1), 3), ('BOTTOMPADDING',(0,0),(-1,-1), 3), ('LEFTPADDING',(0,0),(-1,-1), 5), ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ])) story.append(legend_tbl) story.append(Spacer(1, 5)) # ══════════════════════════════════════════════════════════════════════════════ # SUBTYPE BLOCKS # ══════════════════════════════════════════════════════════════════════════════ # 1. Anti-NMDAR story.append(make_subtype_table( title = "Anti-NMDAR Encephalitis", color = STEEL, pale = PALE_BLUE, abbrev = "NMDAR", clinical_note = "Young women | Ovarian teratoma | Psychiatric onset → seizures → autonomic dysfunction", rows = [ region_row("Occipital lobes", HYPO, '"Wedge-shaped" bilateral hypometabolism – MOST characteristic'), region_row("Parietal lobes / Precuneus", HYPO, "Diffuse; often simultaneous with occipital dropout"), region_row("Posterior cingulate cortex", HYPO, "Deafferentation pattern – can mimic Alzheimer's"), region_row("Frontal lobes", VAR, "Relatively preserved or mildly hyper → creates anteroposterior gradient"), region_row("Temporal lobes (lateral)", HYPO, "Variable; less consistent than occipital"), region_row("Medial temporal lobes (MTL)", VAR, "Less prominent than in LGI1/CASPR2; may be hypo or normal"), region_row("Basal ganglia", VAR, "May show relative hypermetabolism against cortical background"), region_row("Cerebellum", NORMAL, "Usually spared"), [Paragraph("☑ Overall pattern", body_bold), Paragraph("ANTEROPOSTERIOR GRADIENT – front warm, back cold. Diffuse cortical hypometabolism " "is the defining feature. MRI often NORMAL – PET is especially valuable here.", body_sm)], ] )) # 2. Anti-LGI1 story.append(make_subtype_table( title = "Anti-LGI1 Encephalitis", color = TEAL, pale = PALE_TEAL, abbrev = "LGI1", clinical_note = "Older men (~57y) | Faciobrachial dystonic seizures (FBDS) | Hyponatremia | Thymoma <20%", rows = [ region_row("Basal ganglia (caudate + putamen)", HYPER, "HALLMARK – present in 87–100%; often bilateral"), region_row("Medial temporal lobes (hippocampus)", HYPER, "75–82%; ASYMMETRIC in many cases"), region_row("Temporal lobes (lateral)", HYPER, "Common accompaniment"), region_row("Cerebellum", HYPER, "Frequent; may be hypermetabolic"), region_row("Frontal lobes", HYPO, "Frontal hypometabolism as counterpart to limbic hypermetabolism"), region_row("Posterior cingulate / Parietal", HYPO, "Variable, less prominent than in NMDAR"), [Paragraph("☑ Overall pattern", body_bold), Paragraph("Bilateral (asymmetric) MTL + Basal Ganglia HYPER with frontal HYPO. " "Most 'classic' AIE pattern. Asymmetry is a useful clue.", body_sm)], ] )) # 3. Anti-CASPR2 story.append(make_subtype_table( title = "Anti-CASPR2 Encephalitis", color = PURPLE, pale = PALE_PURP, abbrev = "CASPR2", clinical_note = "Middle-aged men | Morvan syndrome | Autonomic dysfunction | Neuromyotonia | Thymoma", rows = [ region_row("Medial temporal lobes", HYPER, "Most frequent – present in ~100% of cases"), region_row("Basal ganglia", HYPER, "100%; similar to LGI1 pattern"), region_row("Bilateral occipital lobes", HYPO, "75% – MORE prominent than in LGI1"), region_row("Frontal lobes", HYPO, "Variable"), region_row("Cerebellum", HYPO, "Can occur – cerebellar hypometabolism"), [Paragraph("☑ Overall pattern", body_bold), Paragraph("MTL + BG HYPER (like LGI1) BUT with prominent bilateral occipital HYPO. " "Anteroposterior gradient also seen. Consider CASPR2 when occipital dropout is striking.", body_sm)], ] )) # 4. Anti-GABA-B story.append(make_subtype_table( title = "Anti-GABA-B Receptor Encephalitis", color = ORANGE, pale = PALE_ORAN, abbrev = "GABA-B", clinical_note = "SCLC in ~50% | Refractory seizures as dominant feature | Middle-aged to elderly", rows = [ region_row("Bilateral hippocampus / amygdala", HYPER, "INTENSE – higher SUVs than other AIE subtypes"), region_row("Temporal lobes", HYPER, "Medial + lateral temporal hypermetabolism"), region_row("Left supramarginal gyrus", HYPO, "Statistically significant vs other subtypes"), region_row("Right parietal lobe", HYPO, "Significant in GABA-B vs anti-Hu group"), region_row("Basal ganglia", NORMAL, "Less prominent than LGI1"), [Paragraph("☑ Overall pattern", body_bold), Paragraph("Intense bilateral hippocampal HYPER (highest SUV of all AIE subtypes) " "+ parietal HYPO. Think GABA-B when seizures are the dominant symptom " "and hippocampal uptake is strikingly bright.", body_sm)], ] )) # 5. Anti-GAD65 story.append(make_subtype_table( title = "Anti-GAD65 Encephalitis", color = GREEN, pale = PALE_GREE, abbrev = "GAD65", clinical_note = "Non-paraneoplastic | Young women | Associated T1DM / autoimmune | Stiff-person / cerebellar ataxia", rows = [ region_row("Medial temporal lobes", HYPER, "54% – less consistent than LGI1/CASPR2"), region_row("Basal ganglia", HYPER, "~10% – less prominent"), region_row("Cerebellum", HYPO, "CHARACTERISTIC when cerebellar ataxia is present"), region_row("Temporal lobes", HYPO, "Temporal hypometabolism can occur"), region_row("Cortex (general)", HYPO, "~35% – mild and less dramatic than NMDAR"), [Paragraph("☑ Overall pattern", body_bold), Paragraph("Fewest PET abnormalities of all AIE subtypes. " "MTL hypermetabolism present but mild. Cerebellar hypometabolism is " "the key differentiating feature when present.", body_sm)], ] )) # 6. Paraneoplastic (Anti-Hu / Anti-Ma2) story.append(make_subtype_table( title = "Paraneoplastic LE – Anti-Hu / Anti-Ma2 (Intracellular Antibodies)", color = CRIMSON, pale = PALE_CRIM, abbrev = "PLE", clinical_note = "Anti-Hu: SCLC | Anti-Ma2: Testicular GCT (young men) | T-cell mediated | Poor Rx response", rows = [ region_row("Bilateral medial temporal lobes", HYPER, "MOST CONSISTENT & INTENSE of all LE types; often striking"), region_row("Striatum / basal ganglia", HYPER, "Common accompaniment"), region_row("Cerebellum", HYPER, "Can be hypermetabolic"), region_row("Brainstem", HYPER, "Especially anti-Ma2; upper brainstem"), region_row("Association cortices", HYPO, "Posterior cingulate, precuneus, frontal – variable"), region_row("Whole-body PET/CT", "⚠ MANDATORY", "Screen for primary tumor in ALL cases"), [Paragraph("☑ Overall pattern", body_bold), Paragraph("Bilateral MTL HYPER is most intense and consistent here vs surface-Ab LE. " "Key distinction: intracellular Ab = T-cell mediated = irreversible. " "Always search for primary tumor on whole-body scan.", body_sm)], ] )) # ── GENERAL PITFALLS BOX ──────────────────────────────────────────────────────── pit_hdr = Table([[Paragraph(" ⚠ PITFALLS & IMPORTANT NOTES", section_hdr)]], colWidths=[16.8*cm]) pit_hdr.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), GOLD), ('TOPPADDING',(0,0),(-1,-1), 4), ('BOTTOMPADDING',(0,0),(-1,-1), 4), ('LEFTPADDING',(0,0),(-1,-1), 6), ])) pitfalls = [ [cb("Peri-ictal scan: Seizure within hours → focal HYPERMETABOLISM at seizure focus – always check EEG timing before calling it AIE"), cb("Recovery phase: Mesiotemporal HYPERMETABOLISM may convert to HYPOMETABOLISM = irreversible post-inflammatory damage (NOT treatment failure)")], [cb("MRI often normal (especially anti-NMDAR): Negative MRI does NOT exclude AIE – PET detects abnormality in 78–100% vs MRI 42–63%"), cb("Posterior cingulate HYPO: Can mimic Alzheimer's disease due to deafferentation – always correlate with clinical context and age of onset")], [cb("Seronegative AIE: PET still abnormal in ~93%; frontal/temporal hypermetabolism supports diagnosis even without antibody confirmation"), cb("Blood glucose: Hyperglycaemia redistributes FDG away from brain → artefactual cortical hypometabolism – note glucose at injection")], [cb("Sedation/ventilation: Diffuse cortical hypometabolism – state of consciousness must be documented"), cb("Use SSP / Z-score maps: Voxel-based analysis detects extra-limbic hypermetabolism missed on visual axial reading alone")], ] pit_tbl = Table(pitfalls, colWidths=[8.4*cm, 8.4*cm]) pit_tbl.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), PALE_GOLD), ('TOPPADDING',(0,0),(-1,-1), 3), ('BOTTOMPADDING',(0,0),(-1,-1), 3), ('LEFTPADDING',(0,0),(-1,-1), 6), ('GRID',(0,0),(-1,-1), 0.2, DIVIDER), ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ('ROWBACKGROUNDS',(0,0),(-1,-1),[PALE_GOLD, colors.white]), ])) story.append(KeepTogether([pit_hdr, pit_tbl, Spacer(1,5)])) # ── QUICK REFERENCE SUMMARY TABLE ────────────────────────────────────────────── sum_hdr = Table([[Paragraph(" QUICK REFERENCE SUMMARY", section_hdr)]], colWidths=[16.8*cm]) sum_hdr.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,-1), SLATE), ('TOPPADDING',(0,0),(-1,-1), 4), ('BOTTOMPADDING',(0,0),(-1,-1), 4), ('LEFTPADDING',(0,0),(-1,-1), 6), ])) sum_col_hdr = [ Paragraph("Subtype", body_bold), Paragraph("Hypermetabolic", body_bold), Paragraph("Hypometabolic", body_bold), Paragraph("Key Differentiator", body_bold), ] sum_rows = [ sum_col_hdr, [Paragraph("Anti-NMDAR", S('X', parent=body_sm, textColor=STEEL, fontName='Helvetica-Bold')), Paragraph("Frontal (relative)", body_sm), Paragraph("Occipital, Parietal, Post.Cing.", body_sm), Paragraph("Diffuse cortical HYPO; wedge occipital; MRI often normal", caption)], [Paragraph("Anti-LGI1", S('X', parent=body_sm, textColor=TEAL, fontName='Helvetica-Bold')), Paragraph("Basal ganglia ✦, MTL (asymmetric)", body_sm), Paragraph("Frontal lobes", body_sm), Paragraph("BG hypermetabolism virtually universal; asymmetry is key", caption)], [Paragraph("Anti-CASPR2", S('X', parent=body_sm, textColor=PURPLE, fontName='Helvetica-Bold')), Paragraph("MTL, Basal ganglia", body_sm), Paragraph("Bilateral occipital ✦, Cerebellar", body_sm), Paragraph("Like LGI1 but prominent occipital HYPO; A-P gradient", caption)], [Paragraph("Anti-GABA-B", S('X', parent=body_sm, textColor=ORANGE, fontName='Helvetica-Bold')), Paragraph("Hippocampus (intense ✦)", body_sm), Paragraph("Parietal, Supramarginal gyrus", body_sm), Paragraph("Highest hippocampal SUV; refractory seizures; look for SCLC", caption)], [Paragraph("Anti-GAD65", S('X', parent=body_sm, textColor=GREEN, fontName='Helvetica-Bold')), Paragraph("MTL (mild)", body_sm), Paragraph("Cerebellum ✦, Temporal", body_sm), Paragraph("Fewest findings; cerebellar HYPO when ataxia present", caption)], [Paragraph("Paraneoplastic\n(Hu/Ma2)", S('X', parent=body_sm, textColor=CRIMSON, fontName='Helvetica-Bold')), Paragraph("Bilateral MTL (most intense ✦)", body_sm), Paragraph("Association cortices", body_sm), Paragraph("Most striking MTL HYPER; whole-body PET mandatory for tumor", caption)], ] sum_tbl = Table(sum_rows, colWidths=[2.6*cm, 3.6*cm, 4.2*cm, 6.4*cm]) sum_tbl.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,0), colors.HexColor('#4A5568')), ('TEXTCOLOR',(0,0),(-1,0), WHITE), ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#F7FAFC'), WHITE]), ('TOPPADDING',(0,0),(-1,-1), 3), ('BOTTOMPADDING',(0,0),(-1,-1), 3), ('LEFTPADDING',(0,0),(-1,-1), 5), ('GRID',(0,0),(-1,-1), 0.3, DIVIDER), ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ('LINEBELOW',(0,0),(-1,0), 1, SLATE), ])) story.append(KeepTogether([sum_hdr, sum_tbl, Spacer(1,5)])) # ── FOOTER ───────────────────────────────────────────────────────────────────── story.append(HRFlowable(width='100%', thickness=0.5, color=DIVIDER, spaceBefore=4, spaceAfter=3)) story.append(Paragraph( "Sources: Bradley & Daroff's Neurology in Clinical Practice; Harrison's Principles of Internal Medicine 22e; " "Solnes et al. J Nucl Med 2017; Baumgartner et al. 2013; Brain Metabolic Alterations in AE (MDPI 2023) | " "Generated by Orris Clinical AI – For educational/reporting reference use only", footer_style )) doc.build(story) print("PDF created successfully.") PYEOF python3 /tmp/workspace/aie-checklist/generate_checklist.py

Editing File

~/aie-checklist/generate_checklist.py

Successfully replaced 1 instance(s) of the string in '/tmp/workspace/aie-checklist/generate_checklist.py'

Running Command

python3 /tmp/workspace/aie-checklist/generate_checklist.py

Your checklist PDF is ready:

AIE FDG PET Checklist

PDF Document · PDF

Here is what's included in the checklist:

Section 1 - Pre-Report Checklist 8 boxes covering patient age/sex, blood glucose, clinical onset, seizure timing, antibody status, sedation status, time from onset, and CT review.

Section 2 - Legend Colour-coded icons: red triangle = hypermetabolism, blue triangle = hypometabolism, yellow = variable, white circle = normal.

Section 3 - Per-Subtype Checklists (one block each) Each block is colour-coded and contains:

Brain region-by-region checklist with expected finding (HYPER / HYPO / VARIABLE)
Inline notes explaining the significance
Summary "overall pattern" row at the bottom

Subtype	Colour
Anti-NMDAR	Blue
Anti-LGI1	Teal
Anti-CASPR2	Purple
Anti-GABA-B	Orange
Anti-GAD65	Green
Paraneoplastic (Hu/Ma2)	Crimson

Section 4 - Pitfalls Box (gold) 8 common traps: peri-ictal scans, recovery phase metabolism flip, normal MRI, posterior cingulate mimicking Alzheimer's, seronegative AIE, blood glucose, sedation, and SSP/Z-score map use.

Section 5 - Quick Reference Summary Table One-row-per-subtype table with hypermetabolic regions, hypometabolic regions, and the key differentiating feature - for fast bedside use.

1-5 questions answers please

Could you clarify what you mean?

Asking for Preferences

What topic should the Q&A cover? · What format do you want?

previous questions which were asked to select before these questions

Got it - you want Q&A on the topics covered in our conversation so far. Here are 5 questions and answers:

Q1. What is the single most important advantage of FDG PET over MRI in autoimmune encephalitis?

A: FDG PET detects brain abnormalities in 78–100% of AIE cases compared to only 42–63% for MRI. This advantage is most pronounced in anti-NMDAR encephalitis, where MRI is frequently completely normal even in severe disease, while PET clearly shows diffuse cortical hypometabolism with an anteroposterior gradient.

Q2. What is the characteristic FDG PET pattern in anti-LGI1 encephalitis and what clinical clue should make you think of it?

A: The hallmark pattern is bilateral (often asymmetric) basal ganglia (caudate + putamen) hypermetabolism present in 87–100% of cases, accompanied by medial temporal lobe hypermetabolism and frontal hypometabolism. The clinical clue is faciobrachial dystonic seizures (FBDS) - brief, frequent dystonic jerks of the face and ipsilateral arm - which are pathognomonic for LGI1 encephalitis. Hyponatremia is another strong bedside clue.

Q3. What is the fundamental difference between paraneoplastic limbic encephalitis (e.g., anti-Hu) and autoimmune limbic encephalitis (e.g., anti-LGI1) in terms of mechanism and treatment response?

A: The key difference lies in where the antibody target is located:

Paraneoplastic (anti-Hu, anti-Ma2): Antibody targets are intracellular - antibodies cannot access them. Damage is caused by cytotoxic T-cells directly killing neurons → irreversible neuronal loss. Treatment is directed at the underlying tumor; immunotherapy response is poor (~1/3 improve).
Autoimmune (anti-LGI1, anti-NMDAR etc.): Antibody targets are on the cell surface - antibodies directly bind, internalize, and functionally disrupt receptors → reversible dysfunction (neurons remain intact). Responds well to steroids, IVIG, plasma exchange, and rituximab.

Q4. A young woman presents with acute psychosis, followed by memory loss, decreased consciousness, orofacial dyskinesias and autonomic instability. MRI is normal. FDG PET shows diffuse posterior cortical hypometabolism with relative frontal preservation. What is the diagnosis, what do you look for on the whole-body CT, and what does the "anteroposterior gradient" mean?

A: The diagnosis is anti-NMDAR encephalitis. On whole-body CT (or PET/CT), look for an ovarian teratoma - present in up to 50% of women under 45. The anteroposterior gradient refers to the PET pattern where the frontal lobes are relatively metabolically preserved (or mildly hypermetabolic) while the parietal and occipital lobes are hypometabolic - creating a visible front-to-back step-down in activity. This is the reverse of normal (where posterior cortices are tonically most active) and reflects preferential NMDA receptor disruption in posterior association areas.

Q5. What is the significance of mesiotemporal hypermetabolism converting to hypometabolism on a follow-up FDG PET in a patient being treated for limbic encephalitis?

A: This is an important distinction:

Mesiotemporal hypermetabolism = active inflammation, ongoing metabolic activity in affected hippocampus - seen in the acute phase
Conversion to hypometabolism on follow-up = irreversible post-inflammatory damage - neurons have been lost and the hippocampus is now metabolically silent (atrophic/scarred)

This does NOT mean treatment failure - it may simply represent the natural evolution from acute inflammation to chronic scarring. In contrast, if PET normalizes (returns to normal uptake), that indicates successful treatment response. This pattern is most important to recognize in paraneoplastic LE (where irreversible damage is more common) but can also occur in surface-antibody AIE if treatment is delayed.

This is a shared conversation. Sign in to Orris to start your own chat.